Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04900337
Other study ID # AMCS-COVID-001
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date February 9, 2021
Est. completion date June 30, 2023

Study information

Verified date February 2024
Source Amorphical Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I/II study with Amorphous Calcium Carbonate (ACC) administered sublingual and in Inhalation concomitantly with BAT (Best Available Care) as Compared to Placebo and BAT for the treatment of Moderate to Severe COVID-19 patients. The purpose of this study is to assess the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC).


Description:

This study includes two parts: Part 1 - A training period of a single arm active treatment open label, to assess the optimal method of study drug administration, as well as the safety of the combined administration, on 5 patients. Following DSMB review of the data collected in part 1 and the DSMB approval to proceed to next part, part 2 will be initiated. Part 2 - A randomized (1:1) placebo controlled 2 arms study. Additional 95 patients will be recruited to this arm. Patients who are hospitalized due to moderate or severe COVID-19 will be recruited to this study. The following elements are the main elements that will be assessed: 1. Confirmation SARS-CoV-2 infection 2. Respiratory Function (breathing rate, SpO2 Oxygen Saturation 3. Vital Signs (BP, HR), Temperature 4. Blood Tests 5. Disease Severity Scale (8 points ordinal scale) The whole study period per patient will be 22 days (21 treatment days) or until the patient has recovered and/or is discharged from the hospital, whichever comes first.


Recruitment information / eligibility

Status Completed
Enrollment 66
Est. completion date June 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Males and females of age = 18 years and = 80 years 2. Signed an Informed Consent 3. Agree to undergo blood tests as per protocol 4. Diagnosed with COVID-19 5. Evidence of lung involvement (by chest X rays or lung US) 6. May or may not need for Supplemental Oxygen at enrollment 7. Hospitalized Exclusion Criteria: 1. Pregnant or breast-feeding females 2. Patients with non-COVID19 related Pneumonia 3. Any pulmonary disease not related to COVID19 4. Tracheostomy 5. High flow oxygen or non-invasive ventilation (Bipap) or Mechanical ventilation 6. Hypercalcemia defined as calcium or corrected calcium > 10.5mg/dL 7. Hyperphosphatemia defined as > 4.5mg/dL 8. Urine calcium to creatinine ratio >0.14 9. Participating in another clinical study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AMOR 18 Powder & Inhalation
AMOR Inhalation x 3 times a day, via Circulaire® II AMOR Powder x 4 times a day, sublingual
Placebo
Placebo Inhalation x 3 times a day, via Circulaire® II Placebo Powder x 4 times a day, sublingual

Locations

Country Name City State
Israel Shamir MC Be'er Ya'aqov
Israel Tel-Aviv Sourasky MC Tel Aviv
Israel Ziv MC Tsefat

Sponsors (1)

Lead Sponsor Collaborator
Amorphical Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Severity rating of Disease using an 8-point ordinal scale on days 7, 14, 21, measured as improvement greater than or equal to 1 point from baseline score. Ordinal 8 points scale:
Not hospitalized and no limitations of activities.
Not hospitalized, with limitation of activities, home oxygen requirement, or both.
Hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons).
Hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (related to Covid-19 or to other medical conditions).
Hospitalized, requiring any supplemental oxygen.
Hospitalized, requiring noninvasive ventilation or use of high-flow oxygen devices.
Hospitalized, receiving invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO).
Death.
Treatment Day 1 to Day 21 or discharge from hospital, the earliest.
Secondary Duration of Hospital stay Time to discharge from hospital Date of hospitalization to treatment day 21 or discharge, whichever comes first.
Secondary Duration of ICU stay Time patient is hospitalized in ICU, if applicable. Treatment Day 1 to treatment day 21 or discharge, whichever comes first.
Secondary Duration of Mechanical Ventilation Use Time the patient requires Mechanical Ventilation (if needed) Treatment Day 1 to treatment day 21 or discharge, whichever comes first.
Secondary Duration of Oxygen Supplementation Time the patient requires Oxygen Supplementation (if needed) Treatment Day 1 to treatment day 21 or discharge, whichever comes first.
Secondary Duration of No Oxygen use Time the patient does not require Oxygen Supplementation Treatment Day 1 to treatment day 21 or discharge, whichever comes first.
Secondary % of patients to meet ordinal scale of 3 or less Proportion of subjects hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control or other nonmedical reasons). Treatment Day 1 to treatment day 21 or discharge, whichever comes first.
Secondary % of death Proportion of subjects died during the study, if any. Treatment Day 1 to treatment day 21 or discharge, whichever comes first.
Secondary Frequency and severity of adverse events Screening to End of treatment day 21 or discharge, whichever comes first.
Secondary Number and percent of patients with hypercalcemia Treatment days 4, 7, 11, 17 and 21.
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3